Core Insights - Intelligent Bio Solutions Inc. (INBS) is progressing towards FDA 510(k) clearance for its Intelligent Fingerprinting Drug Screening System, specifically for opiate codeine, with an anticipated timeline for clearance in the second half of 2026 [2][3] - The company is initiating clinical studies to gather additional data to support its 510(k) submission, with studies expected to conclude in the first half of 2026 [3][4] - INBS's drug testing technology has been adopted by over 450 accounts across 24 countries, indicating a strong global presence and demand for its solutions [4] Company Overview - Intelligent Bio Solutions Inc. specializes in intelligent, rapid, non-invasive testing solutions, aiming to revolutionize portable testing through fingerprint sweat analysis [5] - The Intelligent Fingerprinting Drug Screening System screens for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, providing results in under ten minutes [5] - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport, logistics, mining, drug treatment organizations, and coroners [5]

Group 1 - Cannabix Technologies Inc. has appointed William R. Corl to its board of directors, who is the CEO of Omega Laboratories, a leading drug testing laboratory [1][2] - Cannabix and Omega have been collaborating since May 2024 to commercialize the Marijuana Breath Test (MBT) technology [1][5] - Omega Laboratories has over twenty years of experience in forensic drug testing and holds multiple international certifications [4] Group 2 - Mr. Corl has extensive experience in technology management and has been influential in advancing drug screening regulations [2][3] - The partnership between Cannabix and Omega includes efforts in marketing, distribution, and logistics for the MBT [5] - Cannabix focuses on developing breath testing technologies for recent marijuana use and has also created an alcohol screening device [6]

Core Insights - Intelligent Bio Solutions Inc. has successfully collected new data that reinforces the security and performance of its Intelligent Fingerprinting Drug Screening System, which is crucial for its FDA 510(k) submission [2][5] - The company has engaged in constructive dialogue with the FDA and plans to submit findings along with new data in August [3][5] - The technology utilizes advanced quantification techniques to measure trace sweat volumes, confirming its ability to detect minute levels of sweat in a single fingerprint [4][5] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [6] - The system screens for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, and is designed for safety-critical industries [6] - The company currently supports over 450 accounts across 24 countries and is expanding its global reach through 18 distribution partners [5][6] Regulatory and Technical Developments - The company has completed rigorous cybersecurity testing to validate the resilience of its system, confirming its strength in secure and varied operating environments [3] - The R&D team has invested over 6,000 hours into testing, data aggregation, analysis, and technical reporting to enhance the quality of the FDA submission [5] - The technology is capable of measuring down to 0.0000001 grams, which is approximately 10 million times lighter than a U.S. one-dollar bill, showcasing its precision [4]